Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
2 March 2015 |
Main ID: |
EUCTR2011-000102-21-HU |
Date of registration:
|
08/06/2011 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Safety and efficacy of secukinumab compared to placebo and abatacept in patients with active rheumatoid arthritis who did not respond to anti-TNFa agents
|
Scientific title:
|
A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in patients with active rheumatoid arthritis who have an inadequate response to anti-TNFa agents - NURTURE-1 |
Date of first enrolment:
|
14/07/2011 |
Target sample size:
|
548 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000102-21 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: yes
Other trial design description: Double-dummy
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: yes
Other: no
Number of treatment arms in the trial: 4
|
Phase:
|
|
|
Countries of recruitment
|
Brazil
|
Bulgaria
|
Canada
|
Colombia
|
Czech Republic
|
France
|
Germany
|
Hungary
|
Italy
|
Mexico
|
Romania
|
Russian Federation
|
Slovakia
|
Spain
|
United States
| |
Contacts
|
Name:
|
Public Information Desk
|
Address:
|
Bartók Béla út 43-47.
1114
Budapest
Hungary |
Telephone:
|
+361457-6500 |
Email:
|
infoph.hungary@novartis.com |
Affiliation:
|
Novartis Hungary Kft. Pharma |
|
Name:
|
Public Information Desk
|
Address:
|
Bartók Béla út 43-47.
1114
Budapest
Hungary |
Telephone:
|
+361457-6500 |
Email:
|
infoph.hungary@novartis.com |
Affiliation:
|
Novartis Hungary Kft. Pharma |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Male or non-pregnant, non-lactating female patients
- Presence of rheumatoid arthritis classified by ACR 2010 revised criteria for at least 3 months before screening
- At Baseline : disease activity criteria defined by = 6 tender joints out of 68 and = 6 swollen joints out of 66 WITH at least 1 of the following at screening:
Anti-CCP antibodies positive OR
Rheumatoid Factor positive
AND WITH at least 1 of the following at screening:
hsCRP = 10mg/L
ESR = 28 mm/1st hr
- Patients must have been taking at least one anti-TNFa agents given at an approved dose for at least 3 months before randomization and have experienced an inadequate response to treatment or have been intolerant to at least one administration of an anti-TNFa agent
- Patients must be taking Methotrexate or any other DMARD (but not more than 1 DMARD) for at least 3 months before randomization and have to be on a stable dose at least 4 weeks before randomization (7,5 to 25mg/week for Methotrexate or other DMARD at maximum tolerated dose)
Other protocol-defined inclusion criteria may apply. Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 439 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 109
Exclusion criteria: - Chest x-ray with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician
- Rheumatoid arthritis patients functional status class IV according to the ACR 1991 revised criteria
- Patients who have ever received biologic immunomodulating agents except for those targeting TNFa
- Previous treatment with any cell-depleting therapies
Other protocol-defined exclusion criteria may apply.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Rheumatoid arthritis MedDRA version: 16.1
Level: PT
Classification code 10039073
Term: Rheumatoid arthritis
System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
|
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
|
Intervention(s)
|
Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Powder for solution for injection/infusion INN or Proposed INN: Secukinumab Current Sponsor code: AIN457 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Subcutaneous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use
Trade Name: Orencia Product Name: Abatacept Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: ABATACEPT CAS Number: 332348-12-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use
|
Primary Outcome(s)
|
Main Objective: Demonstrate the efficacy of secukinumab (75 or 150 mg) versus placebo (measured with ACR 20) after 24 weeks of treatment
|
Secondary Objective: Key secondary objectives: - Secukinumab 75mg or 150mg is superior to placebo with respect to change from baseline in DAS28-CRP at Week 24. - Change of the HAQ-DI from baseline on secukinumab 75 mg or 150 mg compared to placebo after 24 weeks - Secukinumab 75mg or 150mg is superior to placebo with regards to the proportion of patients achieving ACR50 at Week 24
|
Primary end point(s): ACR 20
|
Timepoint(s) of evaluation of this end point: Week 24
|
Secondary Outcome(s)
|
Secondary end point(s): First key (ranked) secondary objective: DAS28-CRP
Second key (ranked) secondary objective: HAQ-DI
Final key (ranked) secondary objective: ACR50 responder rate
|
Timepoint(s) of evaluation of this end point: Week 24
|
Secondary ID(s)
|
2011-000102-21-CZ
|
CAIN457F2309
|
Source(s) of Monetary Support
|
Novartis Pharma Services AG
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|